J Korean Med Assoc.  2018 Mar;61(3):214-218. 10.5124/jkma.2018.61.3.214.

Use of progesterone as a preventive medicine and nifedipine as a treatment of preterm labor

• Kim YS

• KMID: 2406976
• DOI: http://doi.org/10.5124/jkma.2018.61.3.214

Abstract

Preterm birth is a major cause of neonatal morbidity and mortality, and occurs in 5% to 15% of all pregnancies. Therefore, its prevention is a major opportunity to reduce medical costs and to promote public health in all countries. Preterm birth is a broad great obstetric syndrome that arises from a wide variety of causes. Although many therapeutic agents are used for premature labor, most of them have serious maternal side effects, and they are ineffective in cases when labor has already begun. Therefore, the authors would like to introduce progesterone, as a treatment to prevent preterm labor. We also investigated whether nifedipine, which is used to treat preterm labor, could prevent preterm labor. We are eager to find more effective and easier-to-use drugs to prevent preterm labor in the future.

Keyword

Obstetric labor, premature; Progesterone; Nifedipine; Prevention & control

MeSH Terms

Female
Mortality
Nifedipine*
Obstetric Labor, Premature*
Pregnancy
Premature Birth
Preventive Medicine*
Progesterone*
Public Health
Nifedipine
Progesterone

Reference

1. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol. 1999; 94:869–877.

2. Freda MC, DeVore N. Should intravenous hydration be the first line of defense with threatened preterm labor: a critical review of the literature. J Perinatol. 1996; 16:385–389.

3. Merkatz IR, Peter JB, Barden TP. Ritodrine hydrochloride: a betamimetic agent for use in preterm labor. II. Evidence of efficacy. Obstet Gynecol. 1980; 56:7–12.

4. Benedetti TJ. Maternal complications of parenteral beta-sympathomimetic therapy for premature labor. Am J Obstet Gynecol. 1983; 145:1–6.

5. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990; 97:149–154.

6. Dodd JM, Flenady VJ, Cincotta R, Crowther CA. Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol. 2008; 112:127–134.

7. Ulmsten U, Andersson KE, Wingerup L. Treatment of premature labor with the calcium antagonist nifedipine. Arch Gynecol. 1980; 229:1–5.

8. Garcia-Velasco JA, Gonzalez Gonzalez A. A prospective, randomized trial of nifedipine vs. ritodrine in threatened preterm labor. Int J Gynaecol Obstet. 1998; 61:239–244.

9. Mesiano S, Wang Y, Norwitz ER. Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? Reprod Sci. 2011; 18:6–19.

10. Jarde A, Lutsiv O, Park CK, Barrett J, Beyene J, Saito S, Dodd JM, Shah PS, Cook JL, Biringer AB, Giglia L, Han Z, Staub K, Mundle W, Vera C, Sabatino L, Liyanage SK, McDonald SD. Preterm birth prevention in twin pregnancies with progesterone, pessary, or cerclage: a systematic review and meta-analysis. BJOG. 2017; 124:1163–1173.

11. Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2008; 48:58–63.

12. Odibo AO, Stamilio DM, Macones GA, Polsky D. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: a cost-effectiveness analysis. Obstet Gynecol. 2006; 108:492–499.

13. Bailit JL, Votruba ME. Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007; 196:219.e1–219.e7.

14. Elovitz M, Wang Z. Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine fetal demise. Am J Obstet Gynecol. 2004; 190:693–701.

15. Elovitz MA, Mrinalini C. The use of progestational agents for preterm birth: lessons from a mouse model. Am J Obstet Gynecol. 2006; 195:1004–1010.

16. Elovitz MA, Mrinalini C. Can medroxyprogesterone acetate alter toll-like receptor expression in a mouse model of intrauterine inflammation? Am J Obstet Gynecol. 2005; 193:1149–1155.

17. Shields AD, Wright J, Paonessa DJ, Gotkin J, Howard BC, Hoeldtke NJ, Napolitano PG. Progesterone modulation of inflammatory cytokine production in a fetoplacental artery explant model. Am J Obstet Gynecol. 2005; 193:1144–1148.

18. Gotkin JL, Celver J, McNutt P, Shields AD, Howard BC, Paonessa DJ, Napolitano PG. Progesterone reduces lipopolysaccharide induced interleukin-6 secretion in fetoplacental chorionic arteries, fractionated cord blood, and maternal mononuclear cells. Am J Obstet Gynecol. 2006; 195:1015–1019.

19. Abate A, Brigandi A, Costabile L, Abate FG, Balzano E, Perino M. 17-alpha-Hydroxyprogesterone caproate and natural progesterone in assisted reproduction: a comparative study. Clin Exp Obstet Gynecol. 1997; 24:190–192.

20. Levy T, Gurevitch S, Bar-Hava I, Ashkenazi J, Magazanik A, Homburg R, Orvieto R, Ben-Rafael Z. Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. Hum Reprod. 1999; 14:606–610.

21. Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol. 2005; 97:421–425.

22. Yassaee F, Shekarriz-Foumani R, Afsari S, Fallahian M. The effect of progesterone suppositories on threatened abortion: a randomized clinical trial. J Reprod Infertil. 2014; 15:147–151.

23. George R, Badawy SZ. Autoimmune progesterone dermatitis: a case report. Case Rep Obstet Gynecol. 2012; 2012:757854.

24. Moini A, Zafarani F, Eslami B, Sadeghi M, Kamyabi Z, Jahangiri N. Comparing intramuscular progesterone, vaginal progesterone and 17-hydroxyprogestrone caproate in IVF and ICSI cycle. Iran J Reprod Med. 2011; 9:119–124.

25. Papatsonis DN, Van Geijn HP, Ader HJ, Lange FM, Bleker OP, Dekker GA. Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstet Gynecol. 1997; 90:230–234.

26. Glock JL, Morales WJ. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol. 1993; 169:960–964.

27. Larmon JE, Ross BS, May WL, Dickerson GA, Fischer RG, Morrison JC. Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. Am J Obstet Gynecol. 1999; 181:1432–1437.

28. Ferguson JE 2nd, Schutz T, Pershe R, Stevenson DK, Blaschke T. Nifedipine pharmacokinetics during preterm labor tocolysis. Am J Obstet Gynecol. 1989; 161:1485–1490.

29. Carr DB, Clark AL, Kernek K, Spinnato JA. Maintenance oral nifedipine for preterm labor: a randomized clinical trial. Am J Obstet Gynecol. 1999; 181:822–827.

30. Sanchez-Ramos L, Kaunitz AM, Gaudier FL, Delke I. Efficacy of maintenance therapy after acute tocolysis: a meta-analysis. Am J Obstet Gynecol. 1999; 181:484–490.